Psychiatr. pro Praxi, 2001; 1: 6-11

Farmakoekonomika, pacienti a psychiatři

MUDr. Jaroslav Vaněk1, MUDr. PhDr. David Vaněk2
1 Psychiatrická a sexuologická ordinace Praha 10
2 Psychiatrická klinika 1. LF UK a VFN Praha

Keywords: health care system, psychiatry, expensiveness, drugs, pharmacoeconomics.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vaněk J, Vaněk D. Farmakoekonomika, pacienti a psychiatři. Psychiatr. praxi. 2001;2(1):6-11.

Zdravotnické systémy se všude na světě dostávají do rozporu mezi potenciální možností poskytovat co nejširší služby i požadavky na ně a schopností tento objem financovat. V České republice se tato disproporce v posledních letech jeví obzvláště výraznou. Pomocí při účinnější alokaci finančních prostředků ve zdravotnictví by se mohly stát farmakoekonomické studie, a to přes všechny své nedokonalosti.

Pharmacoeconomy, patients and psychiatrists

Health care systems all over the world have been experiencing conflict between potential abilities to provide as wide services as possible and capabilities of their financing. In Czech Republic this disproportion has been particularly striking in recent years. Pharmacoeconomic studies could be helpful in more efficient location of financial resources in health care system despite their imperfections.

Psychiatrická a sexuologická ordinace Praha 10

Psychiatrická klinika I. LF UK a VFN Praha

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. OECD Health Data 2000.
    2. Olié J.P., Lery E., Spiesser J.: Cost of a manic episode in bipolar disorder: A French study. AEP Congress Prague 2000. Go to original source...
    3. Greenberg P.E., Stiglin L.E., Finkelstein S.N., Berndt E. R.: The economic burden of depression in 1990. J.Clin. Psychiatry 54, 1993.
    4. Martin P.: La dépression: analyse et intéret des études médico-socio-économiques. L´Inf. Psychiat. 4, 1998.
    5. Miller R.D., Frech H.E.: Is there a link between pharmaceutical consumption and improved health in OECD. Pharmacoeconomics 2000, 18 suppl.1. Go to original source... Go to PubMed...
    6. Vlček J., Macek K., Müllerová H.: Farmakoepidemiologie, farmakoekonomika, farmakoinformatika. Praha 1999.
    7. Zohar J.: New research in PTSD, panic and OCD. ECNP Congress, Paris 1998.
    8. Hosák L.: Farmakoekonomika v psychiatrii, Praha 2000.
    9. Dlouhý M.: Možnosti a meze mezinárodního transferu výsledků farmakoekonomických studií. Remedia suppl. 1998.
    10. Almond S., O´Donnell O.: Cost analysis of the treatment of schizophrenia in the UK. Pharmacoeconomics 1997, 13. Go to original source... Go to PubMed...
    11. Marinkovič O., Timotijevič I.: Amitriptyline vs. moclobemide in depression - a pharmacoeconomic treatment analysis. ECNP Congress, Paris 1998. Go to original source...
    12. Foster R.H., Goa L.G.: A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999, 15. Go to original source... Go to PubMed...
    13. Risperidone Olanzapine Drug Outcomes Studies in schizophrenia (RODOS), 1999.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.